Staidson and Pivotal Collaborate in Trial of Progressive Severe COVID-19 Patients
Staidson and Pivotal have announced a new strategic collaboration to assess Staidson´s investigational product BDB-001 in a Europe-based clinical trial in progressive severe COVID-19 patients caused by SARS-CoV-2. This clinical trial is a multicenter, open-label, randomized and controlled study. Sixty patients will be enrolled in the trial, half of them will be administered the drug and the other half will follow the standard of care used at the corresponding center.
For more information, click here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025 Opening Keynote Panel: What Do Real Patients Actually Talk About?
February 3rd 2025Interactive panel on day 1 of SCOPE Summit 2025 highlighted the need for inclusive narratives, social listening to understand patient experiences, and the role of advocacy groups in opening doors to clinical trials.
